TSLP inhibitor Tezspire clinically has validated Thymic Stromal LymphoPoietin (TSLP) as a valid target for treatment of inflammatory diseases by its approval in late 2021 in the US and in 2022 in ...

OSAKA, Japan and CAMBRIDGE, MA, USA I July 14, 2025 I Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two ...

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo ...

SYDNEY, Australia I July 14, 2025 I Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to ...

Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable ...

Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and ...

SAN DIEGO, CA, USA I July 11, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

BALA CYNWYD, PA, USA I July 08, 2025 I Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing ...

New indication based on results of RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival ...

PALM BEACH GARDENS, FL, USA I July 10, 2025 I Eolas Therapeutics today announced that it has entered into a new agreement with AstraZeneca to assume full development rights to AZD4041, an ...

MIDDLETOWN, DE, USA I July 10, 2025 I Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial ...

ROCKVILLE, MD, USA and SUZHOU, China I July 10, 2025 I Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing ...